Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors
Essam Ghazaly(Queen Mary University of London), Sarah P. Blagden(Churchill Hospital), Victoria K. Woodcock(Churchill Hospital), Laura Spiers(Churchill Hospital), David J. Harrison(NHS Lothian), P. Spilipoulou(Cancer Research UK Scotland Institute), L. Griffiths(Churchill Hospital), Chat Gnanaranjan(London Cancer), Joanna Moschandreas(Nuffield Orthopaedic Centre), T.R.J. Evans(Cancer Research UK Scotland Institute)
Cited by 4
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
High-frequency developmental abnormalities in p53-deficient mice
|Current Biology|1995|467
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222